A history of prostate cancer treatment

Nature Reviews Cancer

Volumn 2, Issue 5, 2002, Pages 389-396

  Denmeade, Samuel R ^a   Isaacs, John T ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ESTRAMUSTINE; ETOPOSIDE; FLUOROURACIL; PACLITAXEL; PROSTATE SPECIFIC ANTIGEN; VINCRISTINE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER SURGERY; HISTOPATHOLOGY; HUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATECTOMY; REVIEW; TREATMENT PLANNING; ART; HISTORY; MALE; PROSTATE TUMOR; RADIOTHERAPY; THERAPY;

ANTINEOPLASTIC AGENTS, HORMONAL; HISTORY, 18TH CENTURY; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HUMANS; MALE; PORTRAITS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY; THERAPEUTICS;

EID: 0036559864     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc801     Document Type: Review

References (84)

1. Adams, J. The case of scirrhous of the prostate gland with corresponding affliction of the lymphatic glands in the lumbar region and in the pelvis. Lancet 1, 393 (1853).
2. Greenlee, R. T., Hill-Harmon, M. B., Murray, T. & Thun, M. Cancer statistics, 2001. CA Cancer J. Clin. 51, 15-36 (2001).
3. Ross, R. K. & Schottenfeld, D. in Cancer Epidemiology and Prevention 2nd edn (eds Schottenfeld, D., Searle, J. G. & Fraumeni, J. F.) 1180-1206 (Oxford Univ. Press, New York, 1997).
4. Huggins, C., Stephens, R. C. & Hodges, C. V. Studies on prostatic cancer: 2. The effects of castration on advanced carcinoma of the prostate gland. Arch. Surg. 43, 209 (1941).
5. Palmer, J. F. (ed.) The Works of John Hunter F. R. S. with Notes (Longman, London, 1837).
6. Lytton, B. Prostate cancer: a brief history and the discovery of hormonal ablation treatment. J. Urol. 165, 1859-1862 (2001).
7. White, W. J. Surgical removal of the hypertrophied prostate. Ann. Surg. 152 (1893).
8. Deming, C. L., Jenkins, R. H. & Van Wagenen, G. Further studies in the endocrinological relationship of prostatic hypertrophy. J. Urol. 34, 678 (1935).
9. Moore, R. A. & McClellan, A. M. Histological study of the effect of the sex hormones on the human prostate, J. Urol. 40, 641 (1938).
10. Gutman, E. B., Sproul, E. E. & Gutman, A. B. Significance of increased phosphatase activity of bone at the site of osteoplastic metastases secondary to carcinoma of the prostate gland. Am. J. Cancer 28, 485-495 (1936).
11. Gutman, A. B. & Gutman, E. B. An 'acid' phosphatase occurring in the serum of patients with metastasizing carcinoma of the prostate gland. J. Clin. Invest. 17, 473-478 (1938).
12. Huggins, C. B. & Clark, P. J. Quantitative studies of prostatic secretion. 11 . The effect of castration and of estrogen injection on the hyperplastic prostate glands of dogs. J. Exp. Med. 72, 747 (1940).
13. Huggins, C. B. & Stevens, R. A. The effect of castration on benign hypertrophy of the prostate in man. J. Urol. 43, 105 (1940).
14. Huggins, C. B. & Hodges, C. V. Studies on prostate cancer: 1. The effects of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1, 203 (1941).
15. Veterans Administration Cooperative Urological Research Group Treatment and survival of patients with cancer of the prostate. Surg. Gynecol. Obstet 124, 1011 (1967).
16. Huggins, C. B. & Scott, W. W. Bilateral adrenalectomy in prostatic cancer: clinical features and urinary excretion of 17-ketosteroids and estrogen. Ann. Surg. 122, 1031 (1945).
17. Schally, A. V., Kastin, A. J. & Arimura, A. Hypothalamic FSH and LH-regulating hormone. Structure, physiology and clinical studies. Fertil. Steril. 22, 703-721 (1971).
18. Schally, A. V. et al. Peptide analogs in the therapy of prostate cancer. Prostate 45, 158-166 (2000).
19. Vilchez-Martinez, J. A., Pedroza, E., Arimura, A. & Schally, A. V. Paradoxical effects of D-Trp6-luteinizing hormone-releasing hormone on the hypothalamic-pituitary-gonadal axis in immature female rats. Fertil. Steril. 31, 677-682 (1979).
20. Sandow, J., Von Rechenberg, W. Jerzabek, G. & Stoll, W. Pituitary gonadotropin inhibition by a highly active analog of luteinizing hormone-releasing hormone. Fertil. Steril. 30, 205-209, (1978).
21. Tolls, G. et al. Tumor growth inhibition in patients with prostatic carcinoma treated with lutenizing hormone-releasing hormone agonists. Proc. Natl Acad. Sci. 79, 1658-1662 (1982).
22. Anonymous. Leuprolide versus diethylstilbestrol for metastatic prostate cancer. The Leuprolide Study Group. N. Engl J. Med. 311, 1281-1286 (1984).
23. Denmeade, S. R. & Isaacs, J. T. in Cancer Medicine 5th edn (eds Bast, R. C. et al.) 765-776 (B. C. Decker, Inc., Hamilton, Ontario, 2000).
24. Sanford, E. J., Drago, J. R., Rohner, T. J. Jr, Santen, R. & Lipton, A. Aminoglutethimide medical adrenalectomy for advanced prostatic carcinoma. J. Urol. 115, 170-174 (1976).
25. Pont, A. et al. Ketoconazole blocks adrenal steroid synthesis. Ann. Intern. Med. 97, 370-372 (1982).
26. Anderson, K. M. & Liao, S. Selective retention of dihydrotestosterone by prostatic nuclei. Nature 219, 277-279 (1968).
27. Bruchovsky, N. & Wilson, J. D. The intranuclear binding of testosterone and 5-α-androstan-17-β-ol-3-one by rat prostate. J. Biol. Chem. 243, 5953-5960 (1968).
28. Mainwaring, W. I. A soluble androgen receptor in the cytoplasm of rat prostate. J. Endocrinol. 45, 531-541 (1969).
29. Steinberg, G. D. & Isaacs, J. T. in Cancer Chemotherapy (eds Hickman, J. A. & Hitton, T. R.) 322-341 (Blackwell Scientific Publications, Oxford, 1993).
30. Varenhorst, E., Wallentin, L. & Carlstrom, K. The effects of orchidectomy, estrogens, and cyproterone acetate on plasma testosterone, LH, and FSH concentrations in patients with carcinoma of the prostate. Scand. J. Urol. Nephrol. 16, 31-36 (1982).
31. Pavone-Macaluso, M. et al. Comparison of diethylstilbestrol, cyproterone acetate and medroxyprogesterone acetate in the treatment of advanced prostatic cancer: final analysis of a randomized phase III trial of the European Organization for Research on Treatment of Cancer Urological Group. J. Urol. 136, 624-631 (1986).
32. Liao, S., Howell, D. K. & Chang, T. M. Action of a nonsteroidal antiandrogen, flutamide, on the receptor binding and nuclear retention of 5 α-dihydrotestosterone in rat ventral prostate. Endocrinology 94, 1205-1209 (1974).
33. Chodak, G. et al. Single agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of prostate cancer. Urology 46, 849 (1995).
34. Seidenfeld, J. et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann. Intern. Med. 132, 566-577 (2000).
35. Labde, F. et al. New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen. Clin. Invest. Med. 5, 267-275 (1982).
36. Lefebvre, F. A. et al. Combined long-term treatment with an LHRH agonist and a pure antiandrogen blocks androgenic influence in the rat. Prostate 3, 569-578 (1982).
37. Crawford, E. D. et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N. Engl. J. Med. 321, 419-424 (1989).
38. Laufer, M., Denmeade, S. R., Sinibaldi, V., Carducci, M. & Eisenberger, M. A. Complete androgen blockade for prostate cancer: What went wrong? J. Urol. 164, 3-9 (2000).
39. Anonymous. Maximum androgen blockage in advanced prostate cancer: an overview of 22 randomised trials with 3,283 deaths in 5,710 patients. Prostate Cancer Trialists' Collaborative Group. Lancet 346, 265-269 (1995).
40. Young, H. H. Four cases of radical prostatectomy. Johns Hopkins Bull. 16, 315 (1905).
41. Millin, T. Retropubic prostatectomy, a new extravesical technique. Lancet 2, 693-696 (1945).
42. Walsh, P. C., Lepor, H. & Eggleston, J. C. Radical prostatectomy with preservation of sexual function: anatomical and pathological considerations. Prostate 4, 473-485 (1983).
43. Wang, M. C. Valenzuela, L. A., Murphy, G. P. & Chu, T. M. Purification of a human prostate specific antigen. Invest. Urol. 17, 159-163 (1979).
44. Papsidero, L. D., Wang, M. C., Valenzuela, L. A., Murphy, G. P. & Chu, T. M. A prostate antigen in sera of prostatic cancer patients. Cancer Res. 40, 2428-2432 (1980).
45. Kuriyama, M. et al. Use of human prostate-specific antigen in monitoring prostate cancer. Cancer Res 41, 3874-3876 (1981).
46. Ragde, H., Aldape, H. C. & Bagley, C. M. Jr. Ultrasound-guided prostate biopsy. Biopty gun superior to aspiration. Urology 32, 503-506 (1988).
47. Minet, H. Application du radium aux tumeurs vesicales, a 1'hypertophle et au cancer de la prostate. Assoc. Franc. Urol. 13, 629 (1909) (in French).
48. Young, H. H. Use of radium in cancer of the prostate and bladder. JAMA 68, 1174-1177 (1917).
49. Pastean, O. & Degrals, De l'emploi du radium dans leur traitemente des cancers de la prostate. J. Urol. Med. Chir. 4, 341 (1913) (in French).
50. Whitmore, W. et al. Retropubic implantation of iodine-125 in the treatment of prostate cancer. J. Urol. 108, 918-920 (1972).
51. Holm, H. et al. Transperineal iodine-125 seed implantation in prostate cancer guided by transrectal ultrasonography. J. Urol. 130, 283-286 (1983).
52. Ragde, H., Grado, G. L., Nadir, B. & Elgamal, A.-A. Modern prostate brachytherapy. CA Cancer J. Clin. 50, 380-393 (2000).
53. George, F. W. et al. Cobalt-60 telecurietherapy in the definitive treatment of carcinoma of the prostate: a preliminary report. J. Urol. 93, 102-109 (1965).
54. Del Regato, J. A. Radiotherapy in the conservative treatment of operable and locally inoperable carcinoma of the prostate. Radiology 88, 761-766 (1967).
55. Bagshaw, M. A., Kaplan, H. S. & Sagerman, R. H. Linear accelerator supervoltage radiotherapy. VII. Carcinoma of the prostate. Radiology 85, 121-129 (1965).
56. Bagshaw, M. A., Ray, G. R., Pistenma, D. A., Castellino, R. A. & Meares, E. M. Jr. External beam radiation therapy of primary carcinoma of the prostate. Cancer 36, 723-728 (1975).
57. Ramakrishna, N. R. & Deweese, T. L. in Prostate Cancer: Biology, Genetics and the New Therapeutics (eds Chung, L., Isaacs, W., Simons, J.) 387-414 (Humana, Totowa, New Jersey, 2001).
58. Pilepich, M. V. et al. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. Urology 45, 616-623 (1995).
59. Pilepich, M. V. et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: Report of Radiation Therapy Oncology Group Protocol 85-31. J. Clin Oncol. 15, 1013-1021 (1997).
60. Bolla, M. et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin N. Engl. J. Med. 337, 295-300 (1997).
61. Feldman, B. J. & Feldman, D. The development of androgen-independent prostate cancer. Nature Rev. Cancer 1, 34-45 (2001).
62. Dowling, A. J. & Tannock, I. F. Systemic treatment for prostate cancer. Cancer Treat. Rev. 24, 283-301 (1998).
63. Schmidt, J. D. et al. Chemotherapy programs of the National Prostatic Cancer Project (NPCP). Cancer 45, 1937-1946 (1980).
64. Scott, W. W. et al. Chemotherapy of advanced prostatic carcinoma with cyclophosphamide or 5-fluorouracil: results of first national randomized study. J. Urol. 114, 909-911 (1975).
65. Murphy, G. P. & Slack, N. H. Response criteria for the prostate of the USA National Prostatic Cancer Project. Prostate 1, 375-382 (1980).
66. Eisenberger M. A. et al. A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J. Clin. Oncol. 3, 827-841 (1985).
67. Tannock, I. F. et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J. Clin. Oncol. 14, 1756-1764 (1996).
68. Kantoff, P. W. et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J. Clin. Oncol. 17, 2506-2513 (1999).
69. Hudes, G. R. et al. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J. Clin. Oncol. 15, 3156-3163 (1997).
70. Hudes, G. R. et al. Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer. J. Clin. Oncol. 10, 1754-1761 (1992).
71. Pienta, K. J. et al. Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. J. Clin. Oncol. 12, 2005-2012 (1994).
72. Sella, A. et al. Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer. J. Clin. Oncol. 12, 683-688 (1994).
73. Savarese, D. M. et al. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B. J. Clin. Oncol. 19, 2509-2516 (2001).
74. Scher, H. I. et al. Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer. J. Natl Cancer Inst. 91, 244-251 (1999).
75. Isaacs, W. B., Xu, J. & Walsh, P. C. In Prostate Cancer: Biology, Genetics and the New Therapeutics (eds Chung, L., Isaacs, W. & Simons, J.) 13-28 (Humana, Totowa, New Jersey, 2001).
76. Brooks, J. D. & Nelson, W. G. in Prostate Cancer. Biology, Genetics and the New Therapeutics (eds Chung, L., Isaacs, W. & Simons, J.) 365-376 (Humana, Totowa, New Jersey, 2001).
77. Greenwald, P. & Lieberman, R. in Prostate Cancer. Biology, Genetics and the New Therapeutics (eds Chung, L., Isaacs, W. & Simons, J.) 499-518 (Humana, Totowa, New Jersey, 2001).
78. Berges, R. S. et al. Implication of the cell kinetic changes during the progression of human prostatic cancer. Clin. Cancer Res. 1, 473-480 (1995).
79. Pinski, J., Parikh, A., Bova, S. & Isaacs, J. T. Therapeutic implications of enhanced G0/G1 checkpoint control induced by coculture of prostate cancer cells with osteoblasts. Cancer Res. 61, 6372-6376 (2001).
80. Denmeade, S. R. & Isaacs, J. T. Enzymatic activation of prodrugs by prostate-specific antigen: targeted therapy for metastatic prostate cancer. Cancer J. Sci. Am. 4 (Suppl. 1), 515-521 (1998).
81. Jakobsen, C. M., Denmeade, S. R., Isaacs, J. T., Olsen, C. E. & Christensen, S. B. Design, synthesis and pharmacological evaluation of thapsigargin analogues for targeting apoptosis to prostatic cancer cells. J. Med. Chem. 44, 4696-4703 (2001).
82. Ruoslahiti, E. & Rajotte, D. An address system in the vasculature of normal tissues and tumors. Annu. Rev. Immunol. 18, 813-827 (2000).
83. Rodriguez, R. et al. Prostate attenuated replication competent adenovirus (ARCA)CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res. 57, 2559-2563 (1997).
84. Simons, J. W. et al. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophase colony-stimulating factor using ex vivo gene transfer. Cancer Res. 59, 5160-5168 (1999).